Mitochondrial dysfunction and consequences in calpain-3-deficient muscle
Open Access
- 11 December 2020
- journal article
- research article
- Published by Springer Nature in Skeletal Muscle
- Vol. 10 (1) , 1-17
Abstract
Background: Nonsense or loss-of-function mutations in the non-lysosomal cysteine protease calpain-3 result in limb-girdle muscular dystrophy type 2A (LGMD2A). While calpain-3 is implicated in muscle cell differentiation, sarcomere formation, and muscle cytoskeletal remodeling, the physiological basis for LGMD2A has remained elusive.Methods: Cell growth, gene expression profiling, and mitochondrial content and function were analyzed using muscle and muscle cell cultures established from healthy and calpain-3-deficient mice. Calpain-3-deficient mice were also treated with PPAR-delta agonist (GW501516) to assess mitochondrial function and membrane repair. The unpairedttest was used to assess the significance of the differences observed between the two groups or treatments. ANOVAs were used to assess significance over time.Results: We find that calpain-3 deficiency causes mitochondrial dysfunction in the muscles and myoblasts. Calpain-3-deficient myoblasts showed increased proliferation, and their gene expression profile showed aberrant mitochondrial biogenesis. Myotube gene expression analysis further revealed altered lipid metabolism in calpain-3-deficient muscle. Mitochondrial defects were validated in vitro and in vivo. We used GW501516 to improve mitochondrial biogenesis in vivo in 7-month-old calpain-3-deficient mice. This treatment improved satellite cell activity as indicated by increased MyoD and Pax7 mRNA expression. It also decreased muscle fatigability and reduced serum creatine kinase levels. The decreased mitochondrial function also impaired sarcolemmal repair in the calpain-3-deficient skeletal muscle. Improving mitochondrial activity by acute pyruvate treatment improved sarcolemmal repair.Conclusion: Our results provide evidence that calpain-3 deficiency in the skeletal muscle is associated with poor mitochondrial biogenesis and function resulting in poor sarcolemmal repair. Addressing this deficit by drugs that improve mitochondrial activity offers new therapeutic avenues for LGMD2A.Keywords
Funding Information
- Foundation for the National Institutes of Health (2R24HD050846-06, 1K26RR032082, 1P50AR060836-01, R01AR055686, 1R56NS097229-01, U54HD090257, 1U54HD071601)
- U.S. Department of War (W81XWH- 09-1-0599, W81XWH-11-1-0809, W81XWH-10-1-0659, W81XWH-11-1-0330, W81XWH-11-1-0782)
- Muscular Dystrophy Association
- Jarvis Crystal Ball
This publication has 59 references indexed in Scilit:
- PPARδ regulates satellite cell proliferation and skeletal muscle regenerationSkeletal Muscle, 2011
- Calpain Protects the Heart from Hemodynamic StressJournal of Biological Chemistry, 2011
- Apoptotic cell death “Nixed” by an ER–mitochondrial necrotic pathwayProceedings of the National Academy of Sciences, 2010
- Down-regulation of MyoD by Calpain 3 Promotes Generation of Reserve Cells in C2C12 MyoblastsJournal of Biological Chemistry, 2010
- Calcium-dependent plasma membrane repair requires m- or μ-calpain, but not calpain-3, the proteasome, or caspasesBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Mechanical membrane injury induces axonal beading through localized activation of calpainExperimental Neurology, 2009
- Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscleHuman Molecular Genetics, 2009
- Calpain 3, the “gatekeeper” of proper sarcomere assembly, turnover and maintenanceNeuromuscular Disorders, 2008
- CREB-1α Is Recruited to and Mediates Upregulation of the Cytochrome c Promoter during Enhanced Mitochondrial Biogenesis Accompanying Skeletal Muscle DifferentiationMolecular and Cellular Biology, 2008
- On the Origin of Cancer CellsScience, 1956